Skip to main content
Skip to footer
About
Active Biotech in Brief
Management
Board of Directors
Goals and Strategy
Corporate Governance
Corporate Governance Report 2025
Article of Association
General Meetings
Audit committee
Scientific committee
Election Committee
Auditors
Projects
Our projects
Tasquinimod
Laquinimod
Naptumomab
Patents
Clinical Studies
Investor
Overview
Analyses and Presentations
Financial Calendar
Financial Reports
Shareholders
Events
Rights Issues
Rights Issue 2025
Media
Overview
Press Contact
Press Releases
Contact
Svenska
BioStock: interview with Helén Tuvesson: Active Biotech kommenterar första doseringen i uppdaterad myelofibrosstudie (in Swedish)
Presentations
14 August, 2026
To the presentation
